A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of SRT2104 (0.03, 0.1,
0.25, 0.5, 1.0, 2.0, and 3.0 g/day) in healthy male volunteers when administered after a
single dose and once daily for 7 consecutive days.
The purpose is also to characterize the pharmacokinetic profile of SRT2104 (0.03, 0.1, 0.25,
0.5, 1.0, 2.0, and 3.0 g/day) after a single dose and multiple administrations in healthy
male volunteers.